On July 23, 2026, a new clinical trial listing was recorded for a study titled "The Effect of Osteoporotic Medications on Vertebral Bone Quality Score," registered as NCT07587775. The trial is a Phase 2 study and its status is listed as enrolling by invitation. Abaloparatide, an approved osteoporosis medication, is included among the osteoporotic medications being examined in this research.
The trial's registration provides details on its design and current recruitment phase, indicating that participants are being enrolled through direct invitation rather than open recruitment. No results or outcome data have been posted for this study at this time.
This update reflects only the administrative and enrollment status of the trial as registered. No efficacy, safety, or comparative findings regarding abaloparatide or other osteoporotic medications have been reported as part of this listing. The trial's focus, based on its title, is on vertebral bone quality score, though no further findings are available at this stage.
For more background on abaloparatide, including its approved uses and general information, readers can refer to the compound overview.